Mirae Asset's spot gold ETF tops $2.5b in net assets
The spot gold exchange-traded fund operated by Global X Australia has garnered over $2.5 billion (3.6 trillion won) in net assets, backed by rising demand for the safe-haven precious metal, Mirae Asset Global Investments announced Wednesday.
Global X Physical Gold is a spot gold ETF operated by Global X Australia under South Korea's leading asset manager, Mirae Asset Global Investments. Launched in 2003 by then-ETF Securities, the fund was the first ETF tied to the gold spot price.
Global X Physical Gold has broadened access to gold investing in the global ETF market, Mirae Asset Global Investments said in a press release.
Though the yellow metal, when held as a physical asset, is considered to have limited liquidity due to the costs of transportation and custody, the ETF has enabled convenient and low-cost gold investing.
With US President Donald Trump's tariff policies kicking in, the price of gold has soared in recent months to a record high, appreciating as a safe-haven asset that can hedge against uncertainties.
Betting on the steady growth of the asset, Mirae Asset Global Investments offers a wide lineup of gold-linked ETFs across the US, Canada and India. Global X Gold Yield is a covered-call ETF and Global X Gold Producers offers exposure to companies involved in the gold mining industry.
"With the ongoing geopolitical tension sparked by the US-China tariff war, gold has been maintaining its presence as a strategic asset along with the US dollar, which is a key currency," said Kim Young-hwan, head of the innovation and global management division at Mirae Asset Global Investments.
"Based on know-how in operating diverse gold-linked ETFs around the world, Mirae Asset will continue to offer new investment opportunities to global investors."
Meanwhile, the asset manager highlighted Global X Australia is a big name in the country's spot commody ETF market. Apart from Global X Physical Gold, the asset manager also operates Global X Physical Silver and Global X Precious Metals Basket, tied to gold, silver, palladium and platinum.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
an hour ago
- Korea Herald
ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore
SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore. This partnership will support venture creation, product development, and commercialisation by bringing together ClavystBio and two national initiatives hosted by A*STAR — MedTech Catapult and the Diagnostics Development Hub (DxD Hub) — along with A*STAR's broader MedTech and venture creation capabilities. The partnership comes amid growing momentum in Singapore's biomedical landscape, with MedTech output reaching S$20 billion in 2023. [1] As Asia's MedTech market is projected to grow to US$225 billion (S$304 billion) by 2030, [2] these efforts aim to better position Singapore-based innovations to scale and enter new markets. Over this two-year partnership, the parties will work towards the co-creation of new MedTech ventures, investments into A*STAR affiliated companies, and fostering collaborations between A*STAR and ClavystBio's portfolio companies. By combining complementary strengths — from research and engineering to venture building and funding — the partnership aims to identify promising technologies, shape MedTech projects for market readiness, and support new venture formation to strengthen Singapore's innovation-driven MedTech ecosystem. The partnership will focus on several key areas: "This partnership highlights ClavystBio's commitment to nurturing globally successful medical devices, digital health, and diagnostics companies from Singapore," said Mr Anselm Tan, Digital Health & MedTech Lead at ClavystBio. "By combining ClavystBio's investment and venture-building expertise with A*STAR's deep scientific capabilities and productisation platforms, we are cultivating an ecosystem primed for innovation and commercial success. "A*STAR is committed to nurturing a dynamic MedTech ecosystem that bridges innovation with deep tech companies," said Ms Irene Cheong, Assistant Chief Executive (Innovation & Enterprise) at A*STAR. "This MoU builds on an existing collaboration with ClavystBio and marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures. Through national productisation platforms like MedTech Catapult and DxD Hub, combined with A*STAR's venture creation capabilities, we aim to commercialise more innovations from lab to market and grow a vibrant MedTech ecosystem in Singapore." About ClavystBio ClavystBio is a life sciences investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing start-ups together, we foster a vibrant and supportive community. About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit About Diagnostics Development Hub (DxD Hub) The Diagnostics Development Hub is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub aims to accelerate the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption. Through impactful products, empowering local enterprises and anchoring global companies in Singapore, DxD Hub contributes to the development of an effective diagnostic devices' ecosystem in Singapore. For ongoing news, visit About MedTech Catapult MedTech Catapult (MC) is a national initiative designed to accelerate the product development and commercialisation of high-value life science instruments and regulated medical devices. MC partners with product owners, local contract manufacturers (CMs), and leverages external design houses, and other key stakeholders to guide innovations from concept to market. Their goal is to strengthen Singapore's medtech ecosystem by providing dedicated engineering, quality assurance, regulatory affairs, clinical affairs, project management and commercialisation support to derisk and support products towards commercialisation and market adoption whilst supporting pull-through to local manufacturing.
Korea Herald
2 hours ago
- Korea Herald
Posco Future M advances supply chain independence with new precursor plant
Facility aims to meet rising demand for China-independent battery materials amid shifting US trade policies Korean battery material manufacturer Posco Future M officially opened its new precursor plant Tuesday in Gwangyang, South Jeolla Province, marking a key step in its efforts to build a self-sufficient supply chain. 'The completion of this precursor plant, following Posco Group's establishment of its own nickel supply chain, marks the realization of a fully self-sufficient system, from raw materials to intermediate products and the finished cathode material,' said Eom Gi-chen, CEO of Posco Future M, during the opening ceremony. 'In today's rapidly changing global supply chain landscape, the Gwangyang precursor plant will enhance the competitiveness and growth of Korea's battery industry.' The 22,400 square meter facility has an annual production capacity of 45,000 metric tons of precursor — a chemically synthesized mixture of metals used in cathode materials — enough to support battery production for 500,000 electric vehicles, the company said. The facility, which has been ramping up operations since May, was largely in operation during a media tour held the same day. The plant was filled with around 50 large metal tanks spread across the factory floor. The precursor production process involves six main steps: dissolving metals in purified water, inducing chemical reactions with catalysts to form precursor crystals, then washing, dehydrating, drying and packaging the final product. 'The reaction process is the core of precursor manufacturing, as it determines the material's density and elemental ratio, both of which are tailored to meet customer specifications,' a company official said, noting Posco Future M's flexibility in adjusting compositions to client needs. Currently, the company uses nickel, cobalt and manganese to produce precursors for NCM cathodes used in electric vehicle batteries, according to the order by Ultium Cells, a US-based 50:50 joint venture between LG Energy Solution and General Motors. 'All precursors produced at this facility are currently supplied to Ultium Cells,' the official added. The company said the timely launch was driven by growing demand from customers for China-independent supply chains, while many other battery projects have been delayed amid sluggish EV demand. The US Inflation Reduction Act disqualifies EV batteries containing materials from 'foreign entities of concern,' including China, from tax credit eligibility. This policy shift has prompted automakers to reduce reliance on Chinese suppliers, who currently dominate 90 percent of the global precursor market. To meet these evolving demands, Posco Future M said it has also secured alternative sources for raw materials used in precursor production. 'We understand the risks automakers face when their supply chains are overly concentrated in China. Regardless of cost considerations, that's where the competitiveness of our plant comes in,' said Lee So-young, head of the business strategy planning group at Posco Future M. 'As US policies continue to evolve, we're working to establish a supply chain that's less exposed to such changes, including sourcing raw materials independently of Chinese suppliers.' The plant's 10 production lines are controlled by about 10 staff members via monitors that provide a real-time overview of the process. With a high degree of automation, the company aims to enhance quality control of its cathod materials — a factor it says was more difficult to achieve when using externally sourced precursors. 'When customers request specific features, many of them cannot be achieved simply by processing third-party precursors,' Lee added. 'We believe our ability to meet those demands in both quality and cost also gives us a key competitive edge.'
Korea Herald
a day ago
- Korea Herald
AmCham delegation heads to Washington for 2025 Doorknock
The American Chamber of Commerce in Korea announced Monday that it will dispatch a business delegation to Washington from June 10 to 12 for its 2025 Washington Doorknock program. The Doorknock is an annual event held in Washington that connects global companies in Korea with US officials to discuss industry issues and strengthen bilateral economic cooperation. This year's visit marks the first such trip following the inauguration of new administrations in South Korea and the United States. The delegation, comprising around 20 senior executives from major global companies including Amazon Web Services, Google, Coupang, Hyundai Motor Group and LG CNS, will engage in a series of meetings with Trump administration officials, members of Congress and leading policy think tanks. Key agenda items include strengthening cooperation in strategic industries such as semiconductors and artificial intelligence, stabilizing supply chains and improving the trade and investment landscape between the two countries. 'This year's Doorknock comes at a pivotal time for Korea-US economic cooperation,' said AmCham Chairman James Kim. 'It's a timely opportunity to directly convey the perspectives of American companies operating in South Korea.' AmCham also plans to advocate for US engagement in the upcoming APEC Summit in Korea and promote greater regulatory alignment and regional collaboration in the Asia-Pacific.
